TN-TYPE-ONE-ENERGY
30.7.2024 14:01:33 CEST | Business Wire | Press release
Type One Energy announced today the final closing of its $82.4 million seed financing round, attracting a broad base of global investors to the Company and its FusionDirect program, which is pursuing a direct path to commercializing fusion energy. FusionDirect is intended to culminate in the launch of Type One Energy’s fusion pilot power-plant project with an owner/operating partner by 2030.
Prominent new shareholders in Type One Energy include Centaurus Capital, GD1 from New Zealand, together with Foxglove and other funds from Australia. This global support highlights the growing international conviction that stellarator fusion technology can play a critical role in completing the transition to a net zero carbon emissions energy system. Fusion energy, unlike traditional nuclear fission, is the power of the stars - fueled from sea water, deployable anywhere, intrinsically safe, and leaving no long-term waste. These unique attributes of fusion energy are what makes the technology increasingly compelling to stakeholders in the future of energy.
The Asia-Pacific (APAC) region features prominently in Type One Energy’s seed financing, with funds from both New Zealand and Australia making first-time investments in fusion energy. The Co-Managing Partner of New Zealand’s GD1 fund, Vignesh Kumar, stated: “The progress Type One Energy has achieved in its FusionDirect program, its access to critical infrastructure such as Oak Ridge National Lab’s supercomputing resources, support from the US DOE Milestone Fusion Development Program, and its focus on advancing the FusionDirect program in the ASEAN region including across New Zealand, made an investment into the team and company a very compelling thesis for us.” Complementing GD1’s decision to become a Type One Energy shareholder, important elements of Australia’s venture capital market joined this financing round. Foxglove’s CEO Gareth Hicks, based in Perth, offered the following comment about Australia’s engagement in Type One Energy: “We are committed to the energy transition, and we want to participate in the value chain of new solutions to key global challenges. Type One Energy’s partner-based approach to fusion commercialization is important to us.”
In addition to bringing new investors into the fusion sector, Type One Energy attracted significant commitments from long-time investors in the industry, including Breakthrough Energy Ventures (BEV) co-founder and founder of Centaurus Capital, John Arnold.
“The successful commercialization of fusion energy will play a critical role in achieving clean, abundant energy,” said Carmichael Roberts, from Breakthrough Energy Ventures. “Stellarator fusion technology now offers the opportunity to directly develop and deploy a fusion pilot power plant without the need to resolve any more fundamental science or engineering challenges and Type One Energy has assembled a great team and strategy to accelerate the deployment of fusion technology globally.”
Type One Energy continues to attract some of the fusion sector’s best technical and business leadership talent. With four locations across North America and ongoing initiatives to further engage global talent, resources and energy transition stakeholders, the company is delivering on its strategy to execute a partner-rich, capital-efficient, decadal path to fusion commercialization.
“By aligning our financing round with rapid, thoughtful expansion of our organizational capabilities, we have been able to demonstrate unique credibility and shareholder value in the private fusion industry,” said Type One Energy Group CEO Christofer Mowry. He added that “we appreciate the confidence of new stakeholders in the success of this essential element of a low carbon future of energy. We have taken the time needed to bring them up the learning curve on this new technology and its path to commercialization.”
About Type One Energy
Type One Energy Group is mission-driven to provide sustainable, affordable fusion power to the world. Established in 2019 and venture-backed in 2023, the company is led by a team of globally recognized fusion scientists with a strong track record of building state-of-the-art stellarator fusion machines, together with veteran business leaders experienced in scaling companies and commercializing energy technologies. Type One Energy applies proven advanced manufacturing methods, modern computational physics and high-field superconducting magnets to develop its optimized stellarator fusion energy system. Our FusionDirect development program pursues the lowest-risk, shortest-schedule path to a fusion power plant over the coming decade, using a partner-intensive and capital-efficient strategy. We are committed to diversity, inclusion, and equitable access to clean energy. For more information, visit www.typeoneenergy.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730842030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
